China-based startup OTR Therapeutics has entered into a strategic collaboration agreement with Korean company LG Chem to accelerate development of novel oncology therapies emerging from China.
The collaboration brings together OTR Therapeutics’ proprietary R&D platform and access to China’s life sciences ecosystem with LG Chem’s global development expertise and commercial infrastructure.
Under the strategic framework, OTR will identify and conduct initial technical assessment of oncology programmes aligned with LG Chem’s strategic priorities. Both companies will then jointly evaluate and license selected programmes.
OTR will lead preclinical and early clinical development, using China’s speed, scientific infrastructure and capital-efficient R&D environment. LG Chem will take a leading role in ex-China clinical development, regulatory strategy and commercialisation.
OTR will receive upfront payments under programme-specific agreements and will be eligible for global development and regulatory milestone payments. The company will also have the option to participate in global development and obtain a share of global rights for programmes that enter late-stage clinical development.
The collaboration is also strategically important for LG Chem Life Sciences. It gives the company a structured way to access China-originated innovation and build a pipeline of oncology assets that may be developed across international markets.
